NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market Tuesday that its third quarter revenues for fiscal year 2015 dipped 2 percent.

For the second quarter in a row, the company also lowered its guidance for the fiscal year.

Total revenues for the three months ended March 31 were $180.0 million compared to $182.9 million in the third quarter of fiscal year 2014. The revenues were below the consensus Wall Street estimate of $183.3 million. Myriad attributed the decrease to severe weather conditions in the northeast during January and February.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.